Clinical trials: Pneumococcal Immunization
Streptococcus Pneumoniae
PICR-b Nasopharyngeal S. Pneumoniae and Nasal S. Aureus Carriage Study
Objective: PCV effects on S. pneumoniae and S. aureus carriage in a population based study. The major specific aims: 1. To compare different PCV vaccination policies, by cross-sectional repeated surveillance of closely related…
- Trial name
- PICRcarriage (NCT03064620)
- Testing
- PCV
- Where
- Israel
- Volunteers
- 12,800 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
The objective of this study is to document the residual burden of acute upper respiratory infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and auditory functional and anatomical abnormalities in…
- Conditions
- Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection, Otitis Media (OM), Invasive Pneumococcal Disease, Protection Against
- Trial name
- Nunavik2 (NCT01694329)
- Where
- Canada
- Volunteers
- 1,420 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who…
- Trial name
- NCT00624819
- Testing
- GSK1024805A, Prevenar, Infanrix hexa
- Where
- 6 sites in Poland
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Kidney Diseases
The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13
Patients with severe chronic kidney disease (CKD) are at a great risk for infection due to their immune system being suppressed.
- Trial name
- NCT02370069
- Testing
- Prevnar 13
- Where
- Canada
- Volunteers
- 138 people
- Sponsor
- Lakehead University
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
There is evidence that aluminum phosphate (AlPO4) contained as an adjuvant in conjugate vaccines enhances the immune response in infants. There is no data so far evaluating whether this also applies to adults.
- Trial name
- NCT00269672
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Volunteers
- 915 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
The purpose of this study will be to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in Canada.
- Trial name
- NCT00475033
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 11 sites in Canada
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Obstructive Pulmonary Disease (COPD)
Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract
The colonization of potential pathogenic bacteria in lower respiratory tract is thought to be accountable for acute exacerbation in subjects with moderate to severe COPD.
- Trial name
- PAEAN (NCT03449459)
- Testing
- oral probiotics, aerosol inhaled amikacin, combined vaccination
- Where
- 3 sites in China
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhongshan Hospital